Zentiva as

Zentiva as maintains a strong liquidity position with a current ratio of 5.9, indicating a robust ability to meet short-term obligations. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure with minimal leverage. Free cash flow is negative at -17.174 million EUR, primarily due to capital expenditures of -4,000 EUR, which may indicate ongoing investment in operations. Profitability metrics show a return on equity (ROE) of 15.67% and a return on assets (ROA) of 12.84%, both exceeding typical industry benchmarks for pharmaceutical firms. These figures suggest efficient use of equity and assets to generate returns. Operating income of 33.242 million EUR and a gross profit of 57.688 million EUR further support the company's strong profitability. Zentiva as operates in a single business segment focused on generic pharmaceuticals, with no disclosed geographic revenue concentration. This lack of segment or geographic diversification may expose the company to specific market risks, though the broad therapeutic areas covered by its portfolio provide some level of diversification. The company's growth trajectory is supported by a strong operating cash flow of 33.058 million EUR and a net income of 17.535 million EUR. Analyst estimates indicate a recent actual revenue of 5.092 billion EUR, suggesting a significant scale of operations. However, the negative free cash flow indicates that the company is currently reinvesting in its operations rather than generating excess cash for distribution. Risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of long-term debt and a strong equity position further mitigate financial risk. The company's dilution potential is also low, with no near-term pressure expected for equity issuance. Recent events include the latest actual EPS of 149.00 EUR and revenue of 5.092 billion EUR, as reported by analysts. These figures reflect the company's current financial performance and market expectations.